glp 1 agonist liraglutide PDB-101: Diabetes Mellitus: Diabetes Mellitus: undefined: Liraglutide Injection Marks Debut as

A comprehensive meta-analysis published in 2017 examining data from over 60,000 patients found no significant increase in pancreatic cancer risk associated with GLP-1 receptor agonist use

Taking the medication first thing in the morning on a truly empty stomach, then waiting the full 30 minutes before eating, optimizes absorption

de Souza AH, Tang J, Yadev AK, Saghafi ST, Kibbe CR, Linnemann AK, Merrins MJ, and Davis DB

For patients particularly those from underserved communities compounded drugs have offered a more accessible option

doi: 10.1001/jamapsychiatry.2024.4789, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar] 161

Reproduction (2015) 150(4):R137148